Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients With Moderate-To-Severe Atopic Dermatitis. J of Skin 2020, 4 (6), s100. https://doi.org/10.25251/skin.4.supp.100.